RPAM
GPCR icon

Rhenman & Partners Asset Management’s Structure Therapeutics GPCR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.79M Buy
145,100
+17,000
+13% +$752K 0.74% 56
2026
Q1 		$6.17M Sell
128,100
-19,500
-13% -$1.33M 0.76% 52
2025
Q4 		$10.3M Sell
147,600
-32,500
-18% -$1.33M 0.96% 39
2025
Q3 		$5.04M Buy
180,100
+45,000
+33% +$896K 0.56% 54
2025
Q2 		$2.8M Buy
135,100
+65,100
+93% +$1.43M 0.35% 63
2025
Q1 		$1.21M Buy
+70,000
New +$1.71M 0.14% 83

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rhenman & Partners Asset Management's GPCR Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Structure Therapeutics (GPCR) stake by 13% in Q2 2026, buying an estimated $752K and bringing the position to 145,100 shares worth $7.79M. The position accounts for 0.74% of the portfolio, ranked #56.

Rhenman & Partners Asset Management first reported a position in GPCR in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.3M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Rhenman & Partners Asset Management held 145,100 shares of Structure Therapeutics worth $7.79M as of Q2 2026.
  • Rhenman & Partners Asset Management bought 17,000 Structure Therapeutics shares in Q2 2026, an estimated $752K.
  • Structure Therapeutics made up 0.74% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #56 holding.
  • Rhenman & Partners Asset Management first reported a position in Structure Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Rhenman & Partners Asset Management's Structure Therapeutics position peaked at $10.3M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.